HORMONES, HORMONE RECEPTORS, AND AGING--HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

在一项对老年女性进行雌激素-前列腺素联合治疗的研究中，30名健康女性， 65-75岁的妇女用倍美力治疗2年， 每日剂量的Provera与30名未经治疗的年龄匹配的BLSA妇女， 对照 DEXA骨丢失率，骨生化指标 周转率、血脂、人体测量和DEXA测定的身体组成， 阴道成熟指数，以及对问卷调查的回答， 观察临床疗效。骨骼中有明显的增加 与骨生物标志物减少相关的矿物质密度 吸收，以及总胆固醇和LDL胆固醇的显着降低 和高密度脂蛋白胆固醇的增加。抑郁症也有所减少， 愤怒，和紧张，如情绪量表的轮廓测量， 血管痉挛症状明显减轻。 常见不良反应 包括乳房肿胀、触痛和阴道出血。 的 对骨骼、脂质和情感有积极影响，副作用最小， 建议老年妇女应纳入未来的随机临床研究， 雌激素使用试验 在一项研究中， 激素调节、骨和矿物质代谢以及葡萄糖和脂质 健康妇女在绝经过渡期的代谢，90名妇女 已完成465次GCRC门诊访视。初步分析 这表明，加速骨质流失可能发生之前停止 月经 已经进行了足够数量的门诊研究访视， 进行纵向数据分析，比较内分泌 骨生物化学、骨密度测量和身体状况 组成评估。 这些分析正在进行中。

In a study of estrogen-progestin co-therapy in older women, 30 healthy women 65-75 years of age were treated for 2 years with Premarin and low dose daily Provera with 30 untreated age-matched BLSA women as controls. Rate of bone loss by DEXA, biochemical indices of bone turnover, plasma lipids, body composition by anthropometry and DEXA, vaginal maturation indices, and responses to questionnaires assessing clinical effects were measured. There were significant increases in bone mineral density which correlated with decreases in biomarkers of bone resorption, as well as significant decreases in total and LDL cholesterol and increases in HDL cholesterol. There were also decreases in depression, anger, and tension as measured by the Profile of Mood Scale and significant decreases in vasomotor symptoms. Frequent adverse effects included breast swelling and tenderness and vaginal spotting. The positive effects on bone, lipids, and affect with minimal adverse effects, suggest that older women should be included in future randomized clinical trials of estrogen use. In a study assessing the longitudinal changes in hormone regulation, bone and mineral metabolism, and glucose and lipid metabolism in healthy women during the menopausal transition, 90 women have completed a total of 465 GCRC outpatient visits. Preliminary analyses suggest that accelerated bone loss may occur prior to the cessation of menses. A sufficient number of outpatient study visits have been performed to warrant longitudinal data analyses comparing the endocrine profiles to the bone biochemistries, bone density measurements, and body composition assessments. These analyses are underway.